Tag: longevity

If it feels like everyone suddenly has a peptide they want to tell you about, you’re not imagining it.

There are peptides for weight loss. Peptides being studied for injury and recovery. Peptides showing up in skincare, longevity conversations and increasingly complicated discussions between friends who, until fairly recently, had never used the word “peptide” in a sentence.

And then there’s Ozempic.

Yes, that belongs in this conversation too.

Which raises a pretty reasonable question: What exactly is a peptide, and how can the same word describe something prescribed by a doctor, something in your face serum and something being sold online for “research purposes”?

The answer is that “peptide” describes an enormous category of molecules, not one type of treatment. And once you understand that distinction, this whole conversation gets a lot easier to navigate.

Okay, so what actually is a peptide?

At its simplest, a peptide is a short chain of amino acids. Amino acids are the same building blocks your body uses to make proteins, so peptides and proteins are closely related. The main difference is size. Peptides are generally smaller.

That sounds almost disappointingly simple considering how much attention they’re getting.

What makes them interesting is what they can do. Your body already makes thousands of peptides, and many of them act as messengers. They help cells communicate and can influence things like hormones, appetite, metabolism, inflammation, immune activity and tissue function.

Think of “peptide” less like the name of a drug and more like the word “vehicle.” A bicycle and a Ferrari are both vehicles, but knowing that doesn’t tell you very much about what either one does.

Peptides are similar. Two compounds can both be peptides and behave completely differently in the body. That’s why saying something is “a peptide” tells us surprisingly little about whether it works, what it does or how well it has actually been studied.

So why does everything suddenly seem to be a peptide?

Part of the answer is that peptide science isn’t actually new. Insulin, one of the most important medicines ever developed, is a peptide hormone. What’s new is how visible this whole category has become.

GLP-1 drugs pushed peptides into everyday conversation in a huge way. Semaglutide, the active ingredient in Ozempic and Wegovy, is a peptide-based medication designed to act like GLP-1, a hormone involved in appetite, blood sugar and digestion.

At the same time, peptides have been showing up everywhere else. You’ll find them in skincare. Researchers are studying different peptides for metabolic disease, inflammation, immune function, tissue repair and other areas. And then there’s a growing group of experimental compounds being discussed online for everything from recovery to longevity.

That last category is where things get messy.

A peptide can be an FDA-approved prescription medication with large human clinical trials behind it. Another may have interesting results in animals but very little human research. Another might be an ingredient in a face cream that never needs to enter your bloodstream at all.

They can all legitimately be called peptides.

They should not all be given the same level of credibility.

That distinction matters, especially now. The internet has a habit of taking “researchers are studying this” and turning it into “this works” somewhere between the laboratory and your Instagram feed.

Our approach at September Wellness is going to be a little less exciting, but a lot more useful. When we look at a peptide, we want to know what kind of evidence actually exists. Was it studied in cells? Animals? Humans? Was there a randomized clinical trial? Is it an approved medication? And just as importantly, what do we still not know?

Not all peptide evidence is created equal.

This is probably the most useful thing to understand before going any further down the peptide rabbit hole: research comes in levels.

A compound might look fascinating in a laboratory experiment. That tells researchers something, but it doesn’t tell us what will happen when a person uses it.

Animal studies take us another step. They can show how a compound behaves in a living system and help researchers figure out whether an idea is worth pursuing. But mice are not tiny humans. Plenty of things that look promising in animals never turn into useful treatments for people.

Human studies are where the conversation gets much more interesting. Even then, there’s a difference between a tiny preliminary study involving 20 people and a large, randomized clinical trial involving hundreds or thousands.

Then there are medications that have made it through the regulatory process, with evidence reviewed for a specific medical use. That doesn’t mean an approved drug is risk-free or that we know everything about it. It means the evidence has reached a very different point than it has for a compound that has only been studied in animals.

This is where peptide conversations online can get confusing. You’ll sometimes hear an impressive biological mechanism described as though it were proof of a real-world benefit. A compound may increase something, decrease something or activate a particular pathway in a laboratory. Interesting? Absolutely. Proof that it will make a healthy 52-year-old feel better? Not necessarily.

A useful way to think about it is as a ladder:

Laboratory research → Animal research → Early human research → Larger clinical trials → Regulatory review and approved medical use

The higher we climb, the more we generally know about what happens in actual people. Some of the peptides getting attention right now are fairly high on that ladder. Others are still standing on the first few rungs.

That doesn’t automatically make the early-stage ones worthless. Some genuinely important medicines began with an interesting experiment and a good question.

It just means we should know which rung we’re standing on before we start talking like we’ve reached the top.

Why peptides are getting our attention now

There’s a reason this conversation is landing differently in our 40s, 50s and 60s.

By this point, most of us have lived in our bodies long enough to notice that the rules have changed a little. Recovery can take longer. Muscle is easier to lose. Sleep can become strangely complicated. Weight may respond differently. Skin changes. Hormones change. Energy changes. Men and women experience some of this differently, but neither gets a free pass.

At the same time, we’re living through an unusually interesting period in medicine. Scientists can target biological pathways with a level of precision that would have sounded fairly futuristic not that long ago. Peptide-based drugs are part of that story.

That combination is powerful. We have a generation of people who still feel young, expect to stay active for decades and aren’t particularly interested in being told that feeling worse is simply part of getting older. Then along comes an expanding world of treatments and research aimed at metabolism, muscle, inflammation, recovery and other processes that become increasingly interesting right around now.

Of course we’re paying attention.

But wanting more options doesn’t mean we have to believe every option works.

That’s the sweet spot we’re interested in: staying curious enough to notice what’s coming, skeptical enough to ask for evidence, and open-minded enough to change our minds when better research arrives.

Approved, compounded and “research use only” are not the same thing

This is where the peptide world can start to feel like alphabet soup.

You’ll see FDA-approved medications. Compounded medications. Products labeled “research use only.” Sometimes they’re discussed in the same conversation, which makes it easy to assume they’re simply different ways of getting roughly the same thing.

They aren’t.

An FDA-approved drug has gone through a formal review process for a particular medical use. The FDA evaluates evidence about its safety and effectiveness, along with how the drug is manufactured and whether its quality can be consistently maintained.

A compounded drug is different. Compounding can serve a legitimate medical purpose. A pharmacist might need to prepare a medication without an ingredient a particular patient can’t tolerate, for example, or create a different dosage form when an approved product doesn’t meet that patient’s needs.

But compounded does not mean FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before they reach patients in the same way it reviews approved drugs.

Then there’s “research use only,” often shortened to RUO.

That phrase is exactly what it sounds like. A product sold for laboratory research is not the same thing as a medication that has been approved for use in people. A certificate showing that a vial contains a particular compound or meets a certain purity measurement does not turn that compound into an approved human treatment.

This is one of those distinctions that sounds obvious once someone says it out loud, but gets surprisingly blurry online.

The compound itself may still be scientifically interesting. Researchers may have good reasons for studying it. There may even be compelling early evidence.

But interesting research and established medical treatment are two different conversations.

Knowing which conversation you’re actually in makes it much easier to evaluate everything that comes next.

So which peptides have we actually heard of?

Probably more than you think.

Insulin is a peptide hormone. So is glucagon. Semaglutide, the medication in Ozempic and Wegovy, is a modified peptide designed to act on the GLP-1 receptor. Tirzepatide, sold as Mounjaro and Zepbound, acts on both GIP and GLP-1 receptors. These are prescription medications backed by extensive human clinical research.

Then there are peptides you may recognize from skincare. Copper peptides such as GHK-Cu have been studied for their roles in skin biology and wound-related processes. Topical peptides also show up in cosmetic products, where the questions about absorption, formulation and evidence are very different from the questions we’d ask about an injected medication.

And then we reach the part of the peptide world that has exploded online.

Names like BPC-157, TB-500, CJC-1295, ipamorelin, MOTS-c and others now circulate in conversations about recovery, body composition, energy, longevity and performance.

Some have genuinely interesting science behind them. Some have human research. Some rely heavily on animal or laboratory studies. Some have far more enthusiasm surrounding them than good clinical evidence.

Which is exactly why putting all of them on a list called “the best peptides” doesn’t make much sense.

It would be a little like making a list of “the best medications” and putting insulin, aspirin, chemotherapy and allergy medicine next to each other. Best for what?

As we build out September Wellness, we’re going to look at these compounds individually. What is it? Why are researchers interested in it? What has actually been studied in humans? What have we learned from animals or laboratory work? What are people claiming that the research hasn’t established yet? And are there meaningful safety questions?

Some will probably look more impressive after that exercise.

Others may look considerably less impressive.

That’s kind of the point.

So what should we take away from all of this?

Peptides aren’t a wellness trend someone invented last Tuesday. They’re part of human biology, they’ve been used in medicine for decades, and peptide research is producing some genuinely important treatments.

What has changed is our access to the conversation.

We’re hearing about experimental compounds much earlier than previous generations ever would have. Research that once stayed mostly inside laboratories and medical journals can become the subject of a podcast, Reddit thread or dinner conversation before there’s much human evidence behind it.

I actually think that’s exciting. We get to learn about where medicine may be going while it’s happening.

We just need to get better at separating possible from proven.

So when you hear about the next peptide that supposedly improves recovery, preserves muscle, changes metabolism, helps skin or somehow makes you feel 35 again, you don’t have to dismiss it.

You also don’t have to believe it.

Ask a better question: What do we actually know so far?

That’s the question we’ll keep coming back to here.

Sources & Further Reading

U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.
Covers the FDA’s current safety concerns and evidence limitations for compounds including BPC-157, CJC-1295, injectable GHK-Cu and ipamorelin.

Naik R, et al. Review of Clinical Pharmacology Information for Peptides Found in US FDA Drug Labeling. Journal of Clinical Pharmacology, 2025.
A review from FDA researchers examining peptide drugs found in U.S. FDA labeling.

Yang Q, et al. Recent advances, strategies, and future perspectives of peptide-based drugs in clinical applications. Chinese Journal of Natural Medicines, 2025.
A recent review of peptide drug development, clinical applications and the challenges involved in translating peptide research into treatments.

Zhang Y, et al. Just how prevalent are peptide therapeutic products? A critical review. International Journal of Pharmaceutics, 2020.
A review of therapeutic peptide products approved by major regulatory agencies, including the FDA, and the different ways peptide medicines are formulated and delivered.